Are mast cells important in diabetes?

Polish Journal of Pathology

Volumn 67, Issue 3, 2016, Pages 199-206

  Kempuraj, Duraisamy ^a   Caraffa, Alessandro ^b   Ronconi, Gianpaolo ^c   Lessiani, Gianfranco ^d   Conti, Pio ^e  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF PERUGIA   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d Center of Sleep Medicine Villa Serena Hospital   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

Author keywords

Autoimmunity; Immune modulation; Mast cells; Peripheral vascular disease; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ANIMAL; DIABETES MELLITUS; HUMAN; IMMUNOLOGY; MAST CELL;

ANIMALS; DIABETES MELLITUS; HUMANS; MAST CELLS;

EID: 84997354334     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: 10.5114/pjp.2016.63770     Document Type: Review

References (83)

1. Conti P, Youinou P, Theoharides TC. Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32). Autoimmun Rev 2007; 6: 131-137.
2. Kahaly GJ, Hansen MP. Type 1 diabetes associated autoimmunity. Autoimmun Rev 2016; 15: 644-648.
3. Kalish RS, Askenase PW. Molecular mechanisms of CD8+ T cell-mediated delayed hypersensitivity: implications for allergies, asthma, and autoimmunity. J Allergy Clin Immunol 1999; 103: 192-199.
4. Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol 2015; 15: 271-282.
5. Oki S, Miyake S. Invariant natural killer T (iNKT) cells in asthma: a novel insight into the pathogenesis of asthma and the therapeutic implication of glycolipid ligands for allergic diseases. Allergol Int 2007; 56: 7-14.
6. Marcinkiewicz J. Cell-mediated immunity: role of IL-3 and IL-6 in the regulation of contact sensitivity reaction. Folia Histochem Cytobiol 1990; 28: 107-119.
7. Clardy SL, Lennon VA, Dalmau J, et al. Childhood onset of stiff-man syndrome. JAMA Neurol 2013; 70: 1531-1536.
8. Craighead JE. Current views on the etiology of insulin-dependent diabetes mellitus. N Engl J Med 1978; 299: 1439-1445.
9. Tahergorabi Z, Khazaei M. Imbalance of angiogenesis in diabetic complications: the mechanisms. Int J Prev Med 2012; 3: 827-838.
10. Di Gialleonardo V, de Vries EF, Di Girolamo M, et al. Imaging of β-cell mass and insulitis in insulin-dependent (Type 1) diabetes mellitus. Endocr Rev 2012; 33: 892-919.
11. Takai S, Jin D, Miyazaki M. Multiple mechanisms for the action of chymase inhibitors. J Pharmacol Sci 2012; 118: 311-316.
12. Gu Y, Yang DK, Spinas E, et al. Role of TNF in mast cell neuroinflammation and pain. J Biol Regul Homeost Agents 2015; 29: 787-791.
13. Venkatesha SH, Dudics S, Weingartner E, et al. Altered Th17/Treg balance and dysregulated IL-1β response influence sus-ceptibility/resistance to experimental autoimmune arthritis. Int J Immunopathol Pharmacol 2015; 28: 318-328.
14. Zheng Z, Huang H, Yu Y, Liang J. Overexpression of FgI2 deteriorates the heart function of experimental autoimmune myocarditis rats. Eur J Inflamm 2015; 13: 66-71.
15. Sannegowda KM, Venkatesha SH, Moudgil KD. Tinospo-ra cordifolia inhibits autoimmune arthritis by regulating key immune mediators of inflammation and bone damage. Int J Immunopathol Pharmacol 2015; 28: 521-531.
16. Theoharides TC, Petra AI, Taracanova A, Panagiotidou S, Conti P. Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther 2015; 354: 24-31.
17. Padgett LE, Broniowska KA, Hansen PA, et al. The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis. Ann N Y Acad Sci 2013; 1281: 16-35.
18. Hober D, Sauter P. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. Nat Rev Endocrinol 2010; 6: 279-289.
19. Ahmadi Z, Arababadi MK, Hassanshahi G. CXCL10 activities, biological structure, and source along with its significant role played in pathophysiology of type I diabetes mellitus. Inflammation 2013; 36: 364-371.
20. Conti P, Pang X, Boucher W, et al. Impact of Rantes and MCP-1 chemokines on in vivo basophilic cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood 1997; 89: 4120-4127.
21. Licari A, De Amici M, Nigrisoli S, et al. Tryptase and histamine may support oral food challenge in the diagnosis of allergy. J Biol Regul Homeost Agents 2015; 29: 1-7.
22. Theoharides TC, Petra AI, Taracanova A, et al. Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther 2015; 354: 24-31.
23. Gu Y, Yang DK, Spinas E, et al. Role of TNF in mast cell neuroinflammation and pain. J Biol Regul Homeost Agents 2015; 29: 787-791.
24. Eskandari N, Tashrifi F, Bastan R, et al. Cyclic nucleotide phos-phodiesterase isoforms in human basophils and mast cells. Int J Immunopathol Pharmacol 2016; pii: 0394632015626150.
25. Toniato E, Spinas E, Saggini A, et al. Immunomodulatory effects of vitamin d on skin inflammation. J Biol Regul Homeost Agents 2015; 29: 563-567.
26. Huh JY, Park YJ, Ham M, Kim JB. Crosstalk between adi-pocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity. Mol Cells 2014; 37: 365-371.
27. Bonnefoy JY, Gauchat JF, Life P, et al. Pairs of surface molecules involved in human IgE regulation: CD23-CD21 and CD40-CD40L. Eur Respir J Suppl 1996; 22: 63-66.
28. Falcone FH, Haas H, Gibbs BF. The human basophil: a new appreciation of its role in immune responses. Blood 2000; 96: 4028-4038.
29. Petra AI, Panagiotidou S, Stewart JM, et al. Spectrum of mast cell activation disorders. Expert Rev Clin Immunol 2014; 10: 729-739.
30. Sykora KW, Tomeczkowski J, Reiter A. C-kit receptors in childhood malignant lymphoblastic cells. Leuk Lymphoma 1997; 25: 201-216.
31. Theoharides TC, Kempuraj D, Tagen M, et al. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 2007; 217: 65-78.
32. Tan SL, Parker PJ. Emerging and diverse roles of protein kinase C in immune cell signalling. Biochem J 2003; 376: 545-552.
33. Zhang J, Shi GP. Mast cells and metabolic syndrome. Biochim Biophys Acta 2012; 1822: 14-20.
34. Walz P, Ladowski JS, Hines A. Distal revascularization and interval ligation (DRIL) procedure for the treatment of ischemic steal syndrome after arm arteriovenous fistula. Ann Vasc Surg 2007; 21: 468-473.
35. Simmons K, Michels AW. Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease. Rheum Dis Clin North Am 2014; 40: 797-811.
36. Shi MA, Shi GP. Different roles of mast cells in obesity and diabetes: lessons from experimental animals and humans. Front Immunol 2012; 3: 7.
37. Chen GT, Han N, Li GF, et al. TNF-α mutation affects the gene expression profile of patients with multiple trauma. Eur J Inflamm 2015; 13: 109-116.
38. Tharp MD. The interaction between mast cells and endothelial cells. J Invest Dermatol 1989; 93: 107-112.
39. Papaccio G. Insulitis and islet microvasculature in type 1 diabetes. Histol Histopathol 1993; 8: 751-759.
40. Shinomiya M, Nadano S, Shinomiya H, Onji M. In situ characterization of dendritic cells occurring in the islets of nonobese diabetic mice during the development of insulitis. Pancreas 2000; 20: 290-296.
41. Möller E, Valugerdi MA, Ridderstad A. Specific and non-specific autoreactive immunity. J Autoimmun 1992; 5: 37-44.
42. Li CR, Baaten BJ, Bradley LM. Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes. J Mol Cell Biol 2012; 4: 38-47.
43. Milovanovic M, Volarevic V, Radosavljevic G. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res 2012; 52: 89-99.
44. Starska K, Brzezińska-Błaszczyk E. The role of stromal mast cells in the modification of CD4+CD25+Foxpł regulatory T cells, Th17 lymphocytes and cytotoxic lymphocytes Tc1 in the development and progression of tumor. Postepy Hig Med Dosw (Online) 2010; 64: 408-416.
45. Sia C, Hänninen A. Functional alterations of proinflammatory monocytes by T regulatory cells: implications for the prevention and reversal of type 1 diabetes. Rev Diabet Stud 2010; 7: 6-14.
46. Noble JA, Johnson J, Lane JA, Valdes AM. HLA class II genotyping of African American type 1 diabetic patients reveals associations unique to African haplotypes. Diabetes 2013; 62: 3292-3299.
47. Lukic ML, Mensah-Brown E, Wei X, et al. Lack of the mediators of innate immunity attenuate the development of autoimmune diabetes in mice. J Autoimmun 2003; 21: 239-246.
48. Conti P, Reale M, Barbacane RC, et al. Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase in mice: lack of effects in genetically mast cell-deficient W/Wv mice. FASEB J 1998; 12: 1693-1700.
49. Hattersley AT, Thorens B. Type 2 diabetes, SGLT2 inhibitors, and glucose secretion. N Engl J Med 2015; 373: 974-976.
50. Zhang J, Shi GP. Mast cells and metabolic syndrome. Biochim Biophys Acta 2012; 1822: 14-20.
51. Ikeda T. The pathogenesis of vitreoretinal diseases from the standpoint of molecular biology. Nippon Ganka Gakkai Zasshi 2003; 107: 785-812.
52. Lee M, Calabresi L, Chiesa G, et al. Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2002; 22: 1475-1481.
53. Conti P, Shaik-Dasthagirisaheb YB. Mast cell serotonin immunoregulatory effects impacting on neuronal function: implications for neurodegenerative and psychiatric disorders. Neurotox Res 2015; 28: 147-153.
54. Hübner MP, Larson D, Torrero MN. Anti-FcεR1 antibody injections activate basophils and mast cells and delay Type 1 diabetes onset in NOD mice. Clin Immunol 2011; 141: 205-217.
55. Shi GP, Bot I, Kovanen PT. Mast cells in human and experimental cardiometabolic diseases. Nat Rev Cardiol 2015; 12: 643-658.
56. Woolley DE. The mast cell in inflammatory arthritis. N Engl J Med 2003; 348: 1709-1711.
57. Qin L, Zhao D, Xu J, et al. The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospon-din-1. Blood 2013; 121: 2154-2164.
58. Au RY, Al-Talib TK, Au AY, et al. Avocado soybean unsapon-ifiables (ASU) suppress TNF-alpha, IL-1beta, COX-2, iNOS gene expression, and prostaglandin E2 and nitric oxide production in articular chondrocytes and monocyte/macrophages. Osteoarthritis Cartilage 2007; 15: 1249-1255.
59. Kohlgruber A, Lynch L. Adipose tissue inflammation in the pathogenesis of type 2 diabetes. Curr Diab Rep 2015; 15: 92.
60. Antonelli A, Ferrari SM, Giuggioli D, et al. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes 2014; 5: 586-600.
61. Tonnel AB, Gosset P, Molet S, et al. Interactions between endothelial cells and effector cells in allergic inflammation. Ann N Y Acad Sci 1996; 796: 9-20.
62. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-614.
63. Reber LL, Sibilano R, Mukai K, Galli SJ. Potential effector and immunoregulatory functions of mast cells in mucosal immunity. Mucosal Immunol 2015; 8: 444-463.
64. Toniato E, Spinas E, Saggini A, et al. Immunomodulatory effects of vitamin d on skin inflammation. J Biol Regul Homeost Agents 2015; 29: 563-567.
65. Xu Y, Chen G. Mast cell and autoimmune diseases. Mediators Inflamm 2015; 2015: 246126.
66. Wesolowski J, Paumet F. The impact of bacterial infection on mast cell degranulation. Immunol Res 2011; 51: 215-226.
67. Rodewald HR, Feyerabend TB. Widespread immunological functions of mast cells: fact or fiction? Immunity 2012; 37: 13-24.
68. Ryba-Stanisławowska M, Stanisławowski M, Myśliwska J. Effector and regulatory T cell subsets in diabetes-associated inflammation. Is there a connection with ST2/IL-33 axis? Perspective. Autoimmunity 2014; 47: 361-371.
69. Manti S, Chimenz R, Salpietro A, et al. Atopic dermatitis: expression of immunological imbalance. J Biol Regul Homeost Agents 2015; 29 (2 Suppl 1): 13-17.
70. Shin JS, Abraham SN. Co-option of endocytic functions of cellular caveolae by pathogens. Immunology 2001; 102: 2-7.
71. Sandig H, Bulfone-Paus S. TLR signaling in mast cells: common and unique features. Front Immunol 2012; 3: 185.
72. Avila M, Gonzalez-Espinosa C. Signaling through Toll-like receptor 4 and mast cell-dependent innate immunity responses. IUBMB Life 2011; 63: 873-880.
73. Abella V, Scotece M, Conde J, et al. The novel adipokine pro-granulin counteracts IL-1 and TLR4-driven inflammatory response in human and murine chondrocytes via TNFR1. Sci Rep 2016; 6: 20356.
74. Dvorak AM. New aspects of mast cell biology. Int Arch Allergy Immunol 1997; 114: 1-9.
75. Garozzo MT, Cuppari C, Filippelli M, et al. Relation of body mass index with ige levels, allergic sensitization and lung function in asthmatic children: our experience and revision of literature. J Biol Regul Homeost Agents 2015; 29: 89-95.
76. Masaki T, Yoshimatsu H. Neuronal histamine and its receptors in obesity and diabetes. Curr Diabetes Rev 2007; 3: 212-216.
77. Woolley DE. The mast cell in inflammatory arthritis. N Engl J Med 2003; 348: 1709-1711.
78. Aronin N, Leeman SE, Clements RS Jr. Diminished flare response in neuropathic diabetic patients. Comparison of effects of substance P, histamine, and capsaicin. Diabetes 1987; 36: 1139-1143.
79. Sismanopoulos N, Delivanis DA, Alysandratos KD, et al. Mast cells in allergic and inflammatory diseases. Curr Pharm Des 2012; 18: 2261-2277.
80. Takai S, Jin D, Miyazaki M. Multiple mechanisms for the action of chymase inhibitors. J Pharmacol Sci 2012; 118: 311-316.
81. Theoharides TC, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 2004; 25: 235-241.
82. Li Z, Zhou J, Zhu D, et al. Role of endogenous TNF-α in car-diomyocyte apoptosis induced by bacteria lipoprotein and the protective effect of IL-10. Eur J Inflamm 2015; 13: 117-125.
83. Zhang C, Liu X, Zhan H, Chen D. Role of dexmedetomide in IL-4 and IFN-g expression in rats with multiple organ dysfunction syndrome induced by postpartum bleeding. Eur J Inflamm 2015; 13: 164-172.